This non-mutated overexpressed antigen has been traditionally used in immunotherapy clinical trials of melanoma patients, testing dendritic cells-based vaccines leading to increased frequencies of circulating MART-1 specific CD8+ and CD4+ T-cells [100]. Here, MLANA is linked to melanoma.